Evolvere Biosciences Analysis: $500K Raised
What is Evolvere Biosciences?
Evolvere Biosciences develops next-generation antibiotics using AI-driven co-evolutionary models. Public profiles describe it as a biotechnology company applying computational biology to therapeutics and synthetic biology. The company appears to be early stage and associated with Y Combinator’s Summer 2024 batch.
Location
Old Road Campus Research Build, Innovation Building, Roosevelt Dr, Oxford OX3 7FZ, United Kingdom
Employees
1-10
Founded
2021
Product Features & Capabilities
- next-generation antibiotics, precision targeting of pathogenic bacteria, combating antimicrobial resistance, rapid generation of antibacterials, dual revenue from therapeutic assets and licensed AI tools
How much Evolvere Biosciences raised
Pre-Seed - $500,000
September 25, 2024Lead Investor: Y Combinator
Who are the founders of Evolvere Biosciences
HQ Full Address
Old Road Campus Research Build, Innovation Building, Roosevelt Dr, Oxford OX3 7FZ, United Kingdom
Market Focus
Evolvere Biosciences primarily focuses on the biotechnology industry, specifically developing innovative therapies in the field of immunology to address unmet medical needs.
Competitors Overview
Evolvere Biosciences has several notable competitors in the health and wellness biosciences market. Key competitors include:
-
BioNTech: Known for its innovative mRNA technology, BioNTech focuses on developing personalized cancer therapies and vaccines. Their advantage lies in their advanced research capabilities and established presence in the vaccine market, particularly with their COVID-19 vaccine.
-
Paratek Pharma: This company specializes in developing and commercializing innovative therapies for patients with serious infections. Their notable advantage is their focus on antibiotic resistance, providing solutions that target resistant bacterial strains.
-
Cyrus Biotechnology: They offer computational tools for protein design and engineering, which can be crucial for developing new bioscience products. Their advantage is in their proprietary technology that enhances the efficiency of protein design.
-
Vividion Therapeutics: This company focuses on developing small molecules that target previously inaccessible proteins. Their unique approach to drug discovery allows them to tackle complex diseases, providing a competitive edge in therapeutic development.
These competitors differ from Evolvere Biosciences in their specific focus areas, technological approaches, and market strategies, which may influence their effectiveness in addressing health and wellness challenges.
Investors
- Cleo Capital
- Y Combinator
- BioEscalator
- Saïd Business School
See something that needs updating? Suggest edits to this profile.